We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Biodesix, Inc. (BDSX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Biodesix, Inc. is one of 924 companies in the Medical group. The Medical group currently sits at #10 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Biodesix, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BDSX's full-year earnings has moved 3.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that BDSX has returned about 136.6% since the start of the calendar year. At the same time, Medical stocks have lost an average of 5.4%. This means that Biodesix, Inc. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Coherus Oncology (CHRS - Free Report) . The stock is up 11.3% year-to-date.
Over the past three months, Coherus Oncology's consensus EPS estimate for the current year has increased 9.6%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Biodesix, Inc. belongs to the Medical Services industry, which includes 66 individual stocks and currently sits at #142 in the Zacks Industry Rank. Stocks in this group have lost about 10.2% so far this year, so BDSX is performing better this group in terms of year-to-date returns.
In contrast, Coherus Oncology falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 444 stocks and is ranked #142. Since the beginning of the year, the industry has moved +1.5%.
Investors with an interest in Medical stocks should continue to track Biodesix, Inc. and Coherus Oncology. These stocks will be looking to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Biodesix, Inc. (BDSX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Biodesix, Inc. is one of 924 companies in the Medical group. The Medical group currently sits at #10 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Biodesix, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BDSX's full-year earnings has moved 3.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that BDSX has returned about 136.6% since the start of the calendar year. At the same time, Medical stocks have lost an average of 5.4%. This means that Biodesix, Inc. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Coherus Oncology (CHRS - Free Report) . The stock is up 11.3% year-to-date.
Over the past three months, Coherus Oncology's consensus EPS estimate for the current year has increased 9.6%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Biodesix, Inc. belongs to the Medical Services industry, which includes 66 individual stocks and currently sits at #142 in the Zacks Industry Rank. Stocks in this group have lost about 10.2% so far this year, so BDSX is performing better this group in terms of year-to-date returns.
In contrast, Coherus Oncology falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 444 stocks and is ranked #142. Since the beginning of the year, the industry has moved +1.5%.
Investors with an interest in Medical stocks should continue to track Biodesix, Inc. and Coherus Oncology. These stocks will be looking to continue their solid performance.